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HLA-NET (a European COST Action) aims at net-
working researchers working in bone marrow trans-
plantation, epidemiology and population genetics to
improve the molecular characterization of the HLA
genetic diversity of human populations, with an
expected strong impact on both public health and
fundamental research. Such improvements involve find-
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International Journal of Immunogenetics, 2012, 39, 459–476databases and computer tools and defining minimal
requirements related to ethical aspects. The overall
outcome is the provision of population genetic charac-
terizations and comparisons in a standard way by all
interested laboratories. This article reports the recom-
mendations of four working groups (WG1-4) of the
HLA-NET network at the mid-term of its activities.
WG1 (Population definitions and sampling strategies for
population genetics’ analyses) recommends avoiding
outdated racial classifications and population names
(e.g. ‘Caucasian’) and using instead geographic and ⁄ or
cultural (e.g. linguistic) criteria to describe human
populations (e.g. ‘pan-European’). A standard ‘HLA-
NET POPULATION DATA QUESTIONNAIRE’ has
been finalized and is available for the whole HLA
community. WG2 (HLA typing standards for popula-
tion genetics analyses) recommends retaining maximal
information when reporting HLA typing results. Rather
than using the National Marrow Donor Program coding
system, all ambiguities should be provided by listing all
allele pairs required to explain each genotype, according
to the formats proposed in ‘HLA-NET GUIDELINES
FOR REPORTING HLA TYPINGS’. The group also
suggests taking into account a preliminary list of alleles
defined by polymorphisms outside the peptide-binding
sites that may affect population genetic statistics
because of significant frequencies. WG3 (Bioinformatic
strategies for HLA population data storage and analy-
sis) recommends the use of programs capable of dealing
with ambiguous data, such as the ‘GENE[RATE]’ computer
tools to estimate frequencies, test for Hardy–Weinberg
equilibrium and selective neutrality on data containing
any number and kind of ambiguities. WG4 (Ethical
issues) proposes to adopt thorough general principles
for any HLA population study to ensure that it
conforms to (inter)national legislation or recommenda-
tions ⁄ guidelines. All HLA-NET guidelines and tools are
available through its website http://hla-net.eu.459
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Our knowledge of the genetic diversity of the human
species has expanded considerably in recent decades,
thanks to the rapid progress in genomic research. The
possibility of genotyping individuals at high resolution
over the entire genome (Altshuler et al., 2010), and
specifically the Major Histocompatibility Complex
(MHC), through a thorough characterization of DNA
sequence variation at human leukocyte antigen (HLA)
genes (The MHC sequencing consortium., 1999; Rob-
inson et al., 2003) has been crucial in addressing
major issues related to biomedicine and molecular bio-
sciences, such as the assessment of genetic susceptibili-
ties to diseases (Segal & Hill, 2003; de Bakker et al.,
2006), the control of haematopoieic stem cell and
organ transplantation (Hansen et al., 1999; Petersdorf
et al., 2003; Mehra, 2010), the appraisal of the
genetic structure of human populations and its mean-
ing (Buhler & Sanchez-Mazas, 2011) and the under-
standing of genomic evolution in relation to the
environment (Meyer & Thomson, 2001, for a review;
Sanchez-Mazas et al., 2012), among other essential
topics. A common goal of these studies is to estimate
HLA genetic diversity within and among human popu-
lations and to describe it through the molecular typing
of population samples.
In this context, a main challenge of tissue typing (or
histocompatibility) laboratories involved in clinical
research (donor–recipient matching) is to produce
HLA molecular data of high quality. Such laboratories
address a crucial health problem in modern societies,
the need for haematopoietic stem cell transplantation
involving the search for HLA compatible donors. Hae-
matopoietic stem cell volunteer donors are generally
recruited randomly in each country with an effort to
constitute very large registries reflecting the HLA vari-
ation over different regions (e.g. Kollman et al., 2004;
Schmidt et al., 2010). In addition, some registries spe-
cifically aim to improve recruitment from ethnic
minorities (e.g. Johansen et al., 2008) to increase the
HLA diversity and hence the probability of finding an
appropriate donor for a given patient. In this context,
knowledge of the distribution of alleles and haplotypes
in many different population groups as determined by
high-resolution typing may allow the design of more
efficient recruitment algorithms.
The accurate description of allelic and haplotypic
HLA profiles and the identification of rare HLA vari-
ants in human populations is not only crucial to recipi-
ent–donor matching and research projects on
histocompatibility. In addition, researchers in at least
two other disciplines share related objectives. Firstly, as
HLA genes play an essential role in susceptibility or
resistance to serious human diseases (Svejgaard et al.,
1996; Blackwell et al., 2009), such as HIV (Carrington
et al., 1999; Kawashima et al., 2009; Pereyra et al.,
2010), their meticulous molecular analysis underpins
epidemiological research. Statistically reliable compari-sons between case and control population samples are
needed to assess the susceptibility (or resistance) con-
ferred by specific HLA alleles. Knowledge of the preva-
lence of a susceptibility allele in a given population is
crucial to evaluate the genetic risk provided by several
different HLA alleles in autoimmunity, infectious dis-
eases or allergic reactions to drugs.
Secondly, HLA genes are of particular interest from a
population genetics point of view to study the genetic
history of the human species and the mechanisms of
molecular evolution (Meyer et al., 2006; Buhler &
Sanchez-Mazas, 2011). Different human populations
exhibit different HLA genetic profiles. This is partly
explained by the geographic dispersal of modern
humans throughout the world and partly by an effect
of natural selection (Meyer et al., 2006; Solberg et al.,
2008; Buhler & Sanchez-Mazas, 2011; Sanchez-Mazas
et al., 2011). Indeed, the evolution of HLA may be dri-
ven by an advantage of specific alleles but also by an
advantage conferred to heterozygous individuals
against a large variety of pathogens (Prugnolle et al.,
2005; Sanchez-Mazas et al., 2012). A precise knowl-
edge of the distribution of allele frequencies in many
different populations may help to understand human
peopling history and the interaction of populations
with their environment in a pathogenic context.
HLA-NET (http://hla-net.eu), a European network
of laboratories involved in the study of HLA for histo-
compatibility, epidemiology and ⁄ or population genet-
ics, was created in 2009 to achieve highly significant
goals in the present research context. Despite their dif-
ferent objectives and applications, all laboratories
involved in this network are united by a common
research task, the description of HLA molecular diver-
sity in human populations, to get accurate reference
data for their own studies in different disciplines and
to provide pan-European data to research groups
working internationally. Moreover, these laboratories
are concerned with similar types of methodological
problems raised by the complexity of HLA polymor-
phism, i.e. how can a population sample for different
applications be defined accurately? How can data be
generated that are comparable to those of other labo-
ratories? How can gene frequencies and other statistics
with highly complex data be estimated? What legal
and ethical rules should be followed to harmonize
with national requirements? HLA-NET is designed to
answer those questions via standardization of proto-
cols and procedures and the development of an elec-
tronic platform to collect, handle, store and process
HLA data and share information amongst European
laboratories. Its final objective is to improve qualita-
tively and quantitatively the collection of HLA-typed
population samples all over Europe and surrounding
areas and to produce a consensual map of HLA
molecular diversity for this broad geographic region.
This article reports the achievements and provides the
main recommendations of HLA-NET at the mid-term
of its activities. The results are presented by four work-ª 2012 Blackwell Publishing Ltd
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to the main issues mentioned above: population defini-
tions and sampling strategies for population genetics
analyses (WG1), HLA typing standards for population
genetics analyses (WG2), bioinformatics strategies for
HLA population data storage and analysis (WG3) and
ethical issues (WG4). A list of laboratories contributing
to the HLA-NET project is also presented.WG1 – Population definitions and sampling
strategies for population genetics’ analyses
Aims of group
Working group 1 (WG1) aims at improving the qual-
ity of population data used in HLA-related studies in
terms of population definition and sampling and at
coordinating the collection of HLA-typed population
samples from Europe and surrounding areas.Population definition and sampling
The establishment of standardized procedures and
questionnaires for collecting and databasing HLA-
typed population samples is essential to fill in the
current lack of comparability among different studies
pursuing similar goals: a reliable estimation of HLA
gene frequencies in samples of healthy individuals to
compare with patients suffering from severe diseases
(HBV, HIV, rheumatoid arthritis, etc.), a reliable esti-
mation of HLA gene frequencies in ethnically or geo-
graphically well-defined populations to reconstruct
human peopling history or a reliable identification of
rare HLA alleles or multilocus haplotypes in distinct
populations to optimize the search of potential donors
in haematopoietic stem cell transplantation.
An important issue is the definition of populations
from an ‘anthropological’ point of view. The group
decided to avoid a priori misclassifications of racial
and ethnic groups in both questionnaires and databas-
es and to consider several levels of description related
to geographic origin, language(s) spoken and any other
relevant information on the ancestry of each studied
population. Outdated racial or ethnic definitions like
‘Caucasian’ are to be replaced with ethically accept-
able alternative names.‘Caucasian’: a meaningless definition. HLA-NET recom-
mends avoiding the term ‘Caucasian’, as well as its
derivatives ‘Caucasoid’ and related terms. To under-
stand the reasons of this recommendation, one has to
bear in mind the complex history of European popula-
tions and their present biological and cultural diver-
sity.
There have been difficult discussions among geneti-
cists on the proportion of Palaeolithic, Mesolithic or
Neolithic ancestry of European populations going
back to very different periods of time (some 40 000,ª 2012 Blackwell Publishing Ltd
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esque et al., 2010; Chikhi et al., 1998, 2002; Pereira
et al., 2005; Richards et al., 2000; Semino et al.,
2000), and such controversies have also been raised by
analyses on ancient DNA (Ammerman et al., 2006;
Barbujani & Chikhi, 2006). Even the proportion of
Neandertal contribution to the genetic pool of modern
Europeans is currently disputed, ranging from no con-
tribution to around 4% of interbreeding between
Neandertals and modern humans (Currat & Excoffier,
2004, 2011; Serre et al., 2004; Green et al., 2010).
Although genetic studies do not yet provide firm con-
clusions to these issues, archaeological data show that
the migrations of Neolithic farmers from the Near
East led to major transformations in diverse aspects of
European life styles (Tresset & Vigne, 2011). Also, the
significant HLA genetic structure observed in present-
day Europeans may possibly trace back to that period
(Buhler et al., 2006).
Europe has been subjected to heterogeneous climates
in the past and is nowadays characterized by temper-
ate to cold temperatures, marked seasons and highly
variable environments. Present-day Europeans are
characterized by a huge phenotypic diversity with pro-
nounced differences, for example, in hair and eye col-
our and body height (with small and tall populations).
Even skin colour varies from relatively dark in some
southern populations to very light in the north. Such
phenotypes were most probably shaped by adaptive
selection to different environments (Sabeti et al.,
2007; Sturm, 2009) although the intensity of selection
may have varied greatly among different traits. Some
other phenotypic traits, which are not visible to the
naked eye because they concern specific molecules
involved in internal metabolic pathways, exhibit un-
usual patterns in Europe. This is the case for lactase
persistence: most southern Europeans cannot digest
milk in adulthood (like most people in the world)
while northern Europeans are perfectly adapted to
milk consumption, and this is because of loss of activ-
ity of the lactase enzyme after weaning in the former
(Ingram et al., 2009). This trait has evolved partly
through natural selection, in coevolution with animal
domestication and ⁄ or through an effect of climate,
and partly as a consequence of the demographic
expansions occurring during the Neolithic period (Ger-
bault et al., 2009, 2011). It also illustrates the high
level of genetic diversity of European populations,
with a frequency of the lactase persistence allele vary-
ing from 0 to almost 80% from south to north.
Europe also exhibits a high cultural complexity,
reflected, for example, by the diversity of the languages
that are spoken today in this continent. There are
almost 50 languages belonging to a dozen families,
some of which belong to unrelated linguistic phyla
including Indo-European, Uralic and Basque (http://eth
nologue.com). The origin of this diversity is not yet fully
understood: for example, there are competing theories
on the origin of Indo-Europeans (do they come from the
462 A. Sanchez-Mazas et al.Near-East or from the north of the Black Sea, or both?)
(Diamond & Bellwood, 2003; Gray & Atkinson, 2003;
Balter, 2004) and the origin of some isolated popula-
tions, such as Basques, is still uncertain.
The history of Europe and its surrounding areas is
so complex and its population diversity so high that
the use of a unique term, ‘Caucasian’, to describe all
populations from Europe and its surrounding areas is
a crude simplification, which is clearly not appropri-
ate. Actually, the term ‘Caucasian’ was first used by
the German naturalist Johann Friedrich Blumenbach
at the end of the 18th century (Gould, 1996). Blumen-
bach, during his journeys, found that the people, and
more particularly the women, living in the Caucasus
were exceptionally wonderful. In his famous book on
The unity of the human genus and its varieties pub-
lished in 1795, he thus described the European variety
as the ‘Caucasian’ variety. Later on, the term ‘Cauca-
sian’ (or its derivatives ‘Caucasoid’, ‘Aryan’, etc.)
remained in the anthropological classifications to
describe a prototype of Europeans (obviously influ-
enced by a racist ideology, with dramatic conse-
quences during world history).
For such reasons, the terms ‘Caucasian’ and its
derivatives have to be deleted from the scientific
vocabulary. HLA-NET proposes to replace them by
the following substitutes, depending on each specific
situation:
1 ‘Europeans’, for populations of European origin
living in Europe;
2 ‘populations of European descent’, for populations
of European origin not living in Europe;
3 ‘populations from (where they are from) living in
Europe’, for populations of non-European origin
living in (where they live) in Europe;
4 ‘North Africans’, ‘West Asians’, ‘populations from
the Near East’ and other geographic names when
populations from these areas surrounding Europe
are concerned;
5 ‘pan-Europeans’, if a general expression is needed
to name at the same time the populations from
Europe and those from its surrounding areas North
Africa, the Near East and Western Asia.‘Black’, ‘Mongoloid’ and other outdated and connoted
terms. Because HLA-NET is a European Action focus-
ing on the HLA molecular characterization of pan-
European populations, we concentrated our discussion
above on the biological and cultural diversity of Euro-
peans and the misuse of the term ‘Caucasian’. However,
our network is also aware that other outdated terms are
commonly used to name groups of populations from
other continents and recommends avoiding them:
‘Black’ or ‘African Black’ (or even ‘Negroid’) are
terms inherited from several centuries (18th to 20th) of
colonial (and racist) anthropology (see, for example,The Outline of History of Mankind, by polygenist Chr-
istoph Meiners, published in German in 1785). Never-
theless, they are still frequently used by researchers to
name sub-Saharan Africans, because of the generally
very dark skin of these populations. Here again, time
has come to definitively abandon such appellations,
which do not correspond to any scientific classification.
Sub-Saharan African populations are highly diverse
from a biological point of view, both in terms of genetic
variation (as most genetic studies have largely demon-
strated) and variation of some quantitative traits includ-
ing, for example, cranial measurements (Relethford &
Harpending, 1994) and hair shape (De la Mettrie et al.,
2007). Although skin colour may also vary significantly
in sub-Saharan Africa (e.g. between East and South
Africans, Khoisan, Pygmies, etc.), this trait has followed
a more peculiar evolution which has been strongly gov-
erned by latitude-dependent natural selection (see, for
example, Parra, 2007; and Rees & Harding, 2012),
explaining its unusual diversity pattern throughout the
world (Relethford & Harpending, 1994). As a result,
very dark-skinned people exist in all continents, from
Africa to Australia via India, Southeast Asia and Mela-
nesia. Taking language as a cultural marker, Africa is
also highly diverse from a cultural point of view, group-
ing 30.5% of the total world languages (http://
www.ethnologue.com) and four main linguistic phyla,
the dispersal of which reveals a complex history of this
continent (Excoffier et al., 1987; Blench, 2006). Similar
to ‘Caucasian’, HLA-NET thus recommends using
terms other than ‘Black Africans’ and derivatives, such
as:1 ‘sub-Saharan Africans’, for populations of African
origin living south of the Saharan Desert;
2 ‘North Africans’, for populations of African origin
living north of the Saharan Desert;
3 ‘West Africans’, ‘South Africans’, ‘East Africans’,
or even more detailed geographic names, for popu-
lations of African origin living in the respective
geographic areas;
4 ‘populations of African descent’, for populations of
African origin not living in Africa.‘Mongoloid’ is also used today in anthropology,
although less frequently than ‘Caucasian’ and ‘Black
African’. It is based on apparent similarities of pheno-
typic traits (such as the epicanthic fold of the eye, very
pronounced in populations from Mongolia) between
all Asian populations, just as ‘Black’ refers to skin col-
our resemblances. Like ‘Caucasian’, ‘Mongolian’,
which is actually correct to name the inhabitants of
Mongolia, but not to name a human race, was used
by Meiners and Blumenbach in their racial classifica-
tions. Both ‘Mongoloid’ and ‘Mongolian’ (taken in
that sense) are again unfortunate relics of the reduc-
tionist views on human variation prevailing in the last
centuries. In agreement with the most commonly usedª 2012 Blackwell Publishing Ltd
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HLA-NET methodological recommendations 463expressions today, we thus propose to replace these
terms and their derivatives by the following appellations:
1 ‘Asians’, for populations of Asian origin living in
Asia;
2 ‘West Asians’, ‘South Asians’, ‘East Asians’,
‘Southeast Asians’, ‘Northeast Asians’, or even
more detailed geographic names, for populations
of Asian origin living in the respective geographic
areas;
3 ‘populations of Asian descent’, for populations of
Asian origin not living in Asia.HLA-NET population data questionnaire. WG1 has
worked on a standard questionnaire to characterize
populations and the population samples collected for
HLA typing, which have to be representative and sta-
tistically reliable. This questionnaire is available at
http://hla-net.eu/population_questionnaire and shown
in Appendix 1. Note that it has been used as a stan-
dard document for AHPD (Analysis of HLA Popula-
tion Data), a project of the 16th International
Histocompatibility and Immunogenetics Workshop
(IHIW).
Basically, one has to provide, for each sample tested
(or to be tested) for HLA:
1 The type of study (i.e. origin of the sample): in
principle, the population samples of interest for
this project are to be defined on specific criteria
based on anthropological field studies (see below
points 1–4); however, for statistical reasons related
to the number of available samples and of individ-
uals per sample, bone marrow registry data can
also be considered and used under clear-cut condi-
tions. Also, collection of patients, although gener-
ally not used for studies in anthropology, may be
useful at a later stage if a specific epidemiological
project is undertaken. They are thus not excluded
a priori. The information on the type of study is
important to know whether a given sample may
include individuals of diverse origins or who share
some peculiar characteristics (e.g. to suffer from a
given disease). Any deviation from Hardy–
Weinberg equilibrium or other unexpected result
may then be better understood. Other important
information is the presence of close (first-degree)
relatives in the sample, as this may impair the esti-
mation of gene frequencies and Hardy–Weinberg
equilibrium. The inclusion of more remote relatives
(cousins, etc.) may also introduce some bias but
cannot be avoided, in particular if samples are
taken from isolated populations studied in the
field, which are often highly endogamous. This is
why we only require a priori the exclusion of first-
degree relatives.ª 2012 Blackwell Publishing Ltd
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sample: we propose the Ethnologue as an excellent
guide to find consensual and alternative names of
the populations under study (although these are lin-
guistic names, they most often correspond to the
used ethnic names). Some alternative names (e.g.
names given by the population to itself or by close
neighbours) may only be known by investigators
working in the field and should also be mentioned.
Of course, population names may be more difficult
to assign in the case of samples of donors or
patients. Then personal comments from the princi-
pal investigator are welcome. In any case, HLA-
NET recommends avoiding outdated racial names
like ‘Caucasian’, ‘Black’, ‘Mongoloid’ and their
derivatives (see above).
3 The geographic location of the population: this has
to be filled in detail (including latitude and longi-
tude). A crucial issue is to know whether a popula-
tion has been sampled in its ‘original’ location or
not (e.g. Chinese living abroad). Of course this
‘original’ homeland may be traced back to only
one or to many generations (e.g. back to the 15th
century for Americans of European descent, etc.).
Detailed information has to be provided in compli-
cated cases.
4 The language spoken by the population: this
should be filled with the help of the Ethnologue
(http://www.ethnologue.com). Some redundancy
may appear with the name of the population (see
point 2 above), but here crucial information is
required concerning the linguistic family.
The same questionnaire then asks information on the
source of DNA samples and HLA typing, and on basic
ethical issues. Detailed comments on these aspects will
be found below in chapters WG2 – HLA typing
standards for population genetics analyses and WG4 –
Ethical issues. A delicate question is that of the num-
ber of individuals tested. We previously proposed a
minimal threshold of 100 individuals (Sanchez-Mazas,
2002) and minimal sample sizes should be kept as
close as possible to this threshold. Note, however, that
more individuals per sample will allow detecting more
alleles (eventually new ones) and will provide much
better frequency estimates.Collection of population data
A final objective of HLA-NET is to create a consen-
sual map of the HLA molecular diversity of European
populations in a broad sense. The population data to
include as part of the HLA-NET project thus concern
in priority:
1 European populations;
2 Populations from surrounding areas, i.e. North
Africa, West Asia, Near-East;
464 A. Sanchez-Mazas et al.3 Populations from other regions of the world but
related to Europe, i.e. local minorities of European
countries such as Congolese in Belgium, etc.
However, HLA-NET is closely related to other projects
conducted at the international level, like the ‘Analysis of
HLA Population Data (AHPD)’ project of the 15th
(Nunes et al., 2010) and 16th International Histocom-
patibility and Immunogenetics Workshop, where popu-
lations from all continents are investigated with the aim
to reconstruct human peopling history. Therefore, pop-
ulation samples from all regions of the world may be
considered by HLA-NET for further collaborations.
A preliminary list of laboratories participating in the
Action and providing population or registry samples
was created on the HLA-NET website through a wiki
for continuous updating. The project started with a
total of 14 European samples: Austrian, Belgian, Bul-
garian, Bulgarian Gipsy, Croatian, Finnish, French,
Greek, Italian, Norwegian, Norwegian Sami, Portu-
guese, Slovenian and Swiss (Table 1). Updates of the
list will be found at http://hla-net.eu. Last but not least,
the group benefited from the help of the European Fed-
eration for Immunogenetics (EFI, http://www.efi
web.eu/) to call for participation by using its services
(mailing list, EFI newsletter) and by inviting HLA-NET
to organize special sessions during its annual confer-
ences (Florence, May 2010; Prague, May 2011).WG2 – HLA typing standards for population
genetics analyses
Aims of group
A major aim of Working Group 2 (WG2) is to define
standards for producing high-quality data for HLATable 1. Preliminary list of population ⁄ registry samples available for HLA-
Name Population Resolution Reporting
G. Fischer Austrian (registry) Intermediate List of am
M. Toungouz
Nevessignsky





High List of am
Z. Grubic Croatian High No ambig
M.L. Lokki Finnish High List of am
V. Dubois French (registry) Intermediate NMDP c
C. Papasteriades Greek High No ambig






Intermediate List of am
B. Vidan-Jeras Slovenian High List of am
J.M. Tiercy Swiss (registry) Intermediate List of am
n.a.: not applicable.genotyping and set up criteria for typing methods used
for each population, thus allowing population compar-
isons in meta-analyses. These tasks involve careful
comparisons of genetic typing methodologies and their
ability to produce results at comparable resolution lev-
els; they also address the search for strategies to han-
dle ambiguous data and interpret heterogeneous HLA
genotypes because of the very high level of complexity
of this polymorphism and the adoption of universal
and user-friendly formats.Reporting typing ambiguities
The group worked on the issue of reporting typing
ambiguities in a format that is best suitable for haplo-
typic and allelic frequency estimation, intra- and inter-
population genetics analyses.
While the gold standard is exon 2 + 3 (class I) and
exon 2 (class II) sequencing, populations may be anal-
ysed by other methods, such as reverse SSO hybridiza-
tion on microbeads arrays (luminex technology). This
latter method also targets exons 2 + 3 (class I) and
exon 2 (class II) polymorphisms, although it can be
extended to type for exons 4-7. It is ideally suited for
typing large numbers of samples, but it leads to typing
ambiguities in most cases, because of the ever increas-
ing allelic polymorphism. Similarly, bi-allelic sequenc-
ing also leads to ambiguities that may be resolved
using additional primers for the sequencing reactions
when polymorphisms are located within the amplicon
(Voorter et al., 2007). Ambiguities involving polymor-
phisms located outside exons 2 + 3 (class I) or exon 2
(class II) require longer range PCR and additional
sequencing reactions. Whatever the technique used it
is recommended that all the ambiguities are reported.
This is generally achieved using the National MarrowNET
results Technique SBT class I SBT class II





biguities SBT, SSO Exons 2-4,
biallelic
Exon 2, biallelic
uities SSO, SSP n.a. n.a.
biguities SBT n.a. Exon 2, biallelic
odes SBT Biallelic Biallelic
uities SSP, SSO n.a. n.a.




odes SSP, SSO n.a. n.a.
biguities SBT, SSO Exons 2-4 Exons 2-3




biguities SSO, SSP n.a. n.a.
ª 2012 Blackwell Publishing Ltd
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Table 2. List of alleles (nonexhaustive) that were usually not taken
into account in the past but may affect population genetic statistics
because of significant frequencies
Allele Populations




C*07:06 Pan-European ⁄ West Asian




HLA-NET methodological recommendations 465Donor Program (NMDP) coding system, i.e. abbrevia-
tion codes for the so-called ambiguous allele groups.
Although certainly helpful for its original purpose of
simplifying the identification of matched bone marrow
donors, its use in practice increases artificially the
number of allele pairs for a given genotype prior to
haplotypic and ⁄ or allelic frequency estimation. To
retain maximal information, it is strongly recom-
mended to provide the list of allele pairs required to
explain the genotype, as this will not include spurious
allele pairs resulting from the expansion of the abbre-
viation codes.
An example of the importance of defining an
adequate ambiguity notation as a standard procedure
is provided in Figure 1 for two alternative outputs
proposed by the reverse SSO microbead array typing.
Based on the above considerations, guidelines and
recommendations of WG2 for reporting HLA typing
ambiguities are given in Appendix 2 and can be found
at http://hla-net.eu/reporting_HLA_typings_guidelines.
Based on the IMGT ⁄ HLA database, a list of ambi-
guities that comprise polymorphisms outside exons
2 + 3 for class I and exon 2 for class II at each HLA
locus has been generated. In a second step each of
these alleles differing outside the sequence defining the
peptide-binding site was screened for its occurrence in
available population databases. While a majority of
these belonged to the rare or very rare allele groups,
several alleles were identified as occurring at signifi-Patient ID: Sample ID: ###############
























































Figure 1. Illustration of the importance of defining an adequate and stand
posed by the reverse SSO microbead array typing method.
ª 2012 Blackwell Publishing Ltd
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alleles is shown in Table 2.
Whether the discrimination of these alleles has an
input on population comparisons remains to be eluci-
dated. Some data are already available showing that
the relative frequencies of the DRB1*14:01 and 14:54
alleles differ widely among populations, with the
DRB1*14:01 extremely uncommon in American popu-
lations from Asian descent but more frequent (up to
15%) in spanish speaking American populations (Xiao
et al., 2009). In Europe a recent survey of 106 Ger-
man donors with DRB1*14:01 ⁄ 14:54 ambiguous ty-/43N/53N/59/60/62/64/66/67/74/75/82N/83N/85/89
ossible allele pairs (at 4 digits) when
codes are expanded 
sible allele pairs (at 4 digits), or 44 (at 6–8
, are required to explain the genotype
and A*24:34 are observed only with A*02:34 and 
and not with the other A*02 alleles listed above
Abbreviated notaon
« user friendly » 
but results in a big loss of 
informaon   
ard notation procedure for ambiguities in two alternative outputs pro-
466 A. Sanchez-Mazas et al.pings found 87.9% to be DRB1*14:54 (Furst et al.,
2010).Reporting rare alleles
As a 15th IHIW project, data were collected on the
frequency of supposedly rare HLA alleles, and the
final analysis showed that 40.8% of the 2977 HLA
alleles (Release 2.23.00, Oct. 2008) have been
sequenced only once and should therefore be consid-
ered as very rare (Middleton et al., 2009). In a previ-
ous ASHI study, 27-30% of the HLA-A, B, C, DRB1
alleles have been classified as common (frequency
>0.0001) or well-documented (observed at least three
times) (Cano et al., 2007).
Through HLA-NET, rare alleles have been submit-
ted to Derek Middleton and Faviel Gonzalez-Galarza
and included in the http://www.allelefrequencies.net
database (Gonzalez-Galarza et al., 2011). In total,
193 distinct alleles have been submitted (Table 3) and
70 of these submissions allowed the confirmation of
an allele which had never been reported after its initial
submission to IMGT ⁄ HLA (Robinson et al., 2003).Available population samples
A list of available HLA-typed European population
samples has been provided by WG2 members and will
be available for the project. As shown in Table 1, 14
different populations were initially provided, with var-
ious typing techniques and number of individuals, but
with high resolution typing for most populations. The
list is currently being updated (see chapter WG1 –
Population definitions and sampling strategies for
population genetic analyses, point 2: Collection of
population data).Table 3. Rare alleles contibuted to the http://www.allelefrequen-
cies.net database






B. Lie Oslo Norway 5 5 SSP
B. Vidan-Jeras Ljubljana Slovenia 4 3 SBT, SSP
C. Papasteriades Athens Greece 7 3 SSP
D. Ligeiro Lisbon Portugal 27 27 SBT, SSP
F. Poli Milan Italy 38 30 SBT, SSP
G. Fischer Vienna Austria 26 26 SBT
J.-M. Tiercy Geneva Switzerland 1 1 SBT
M.-L. Lokki Helsinki Finland 3 3 SBT




Leiden Netherlands 76 66 SBT
V. Dubois Lyon France 50 45 SBT
Z. Grubic Zagreb Croatia 3 3 SSP, Other
Total 246 218*
*Taking into consideration all submissions, 193 distinct alleles were
submitted.WG3 – Bioinformatic strategies for HLA
population data storage and analysis
Aims of group
The complexity of the HLA polymorphism is due to
the existence of hundreds or thousands of different
alleles at various loci and because new alleles are con-
stantly discovered. As a consequence, HLA population
data are neither stored nor analysed in a standard way
in different laboratories, which makes comparisons
very difficult. To use the large amount of data pro-
duced by different laboratories, in an optimized and
comparable way, public access to specific computer
facilities, continuously updated in relation to the ever-
increasing HLA allelic record and new developments
in data analysis, is required. Working group 3 (WG3)
was charged of two types of tasks: first, to provide the
computer infrastructure to HLA-NET and the minimal
tools required to support the work of the other work-
ing groups and second, to develop the databases and
computer tools required for storing and analysing the
HLA data, in particular the statistical methods and
computer programs necessary to validate and report
data with the highest level of reliability.HLA-NET infrastructure
The website of HLA-NET (http://hla-net.eu) is a wiki
that is used to support all activities, e.g. scheduling
meetings, reporting results, publishing documents, pro-
viding access to computer programs and disseminating
information, among others. The wiki simplifies the
participation of HLA-NET members to the project,
making coordination possible for both small and large
contributions, such as correcting typos or creating new
sections of the site, respectively. In a further step, this
integrated web platform will be connected to the
databases that Derek Middleton and Alicia Sanchez–
Mazas’ groups are currently harmonizing (Gonzalez-
Galarza et al., 2011; Vangenot, C., Weber, O. S.,
Sanchez-Mazas, A. & Nunes, J. M. In prep.). This
harmonization is conceived in a way to include a num-
ber of computer programs for routine validations and
analyses of HLA and other immunogenetics data. In
this way, new data implemented in the future will be
automatically processed according to HLA-NET stan-
dard recommendations. To understand such recom-
mendations, we review below some crucial questions
that we had to face in this part of the project.Dealing with heterogeneous, ambiguous and low sample-sized data
The data collections are of diverse types, i.e. both fre-
quency and genotypic data, and the level of resolution
is quite diverse. We believe that to maintain an accept-
able balance between financial cost and precision of
typings, most laboratories will continue to type HLA
at intermediate resolution levels including ambiguities,ª 2012 Blackwell Publishing Ltd
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Table 4. Allele frequency thresholds (in %) below which the 95%
confidence interval contains 0, as a function of sample size (N) and
sampling model: I) standard normal two-tail; II) normal one-tail; III)
exact binomial. Alleles exhibiting these and smaller allelic frequen-
cies have probabilities larger than the usual 5% of being missed (0
alleles) in samples of the corresponding sizes
Allele frequencies
N Model I (%) Model II (%) Model III (%)
30 6.25 4.43 4.85
50 3.85 2.75 2.95
100 1.96 1.37 1.48
150 1.32 0.92 1.00
200 0.99 0.69 0.75
500 0.39 0.28 0.30
N, number of individuals in the sample.
HLA-NET methodological recommendations 467at least until next generation sequencing is routinely
used. Therefore, considerations related to the treat-
ment of ambiguous data are not only of interest in the
present but also in the foreseeable future.
One aspect of this issue relates to the above-men-
tioned standardization and reporting HLA typing
results (including the identification of kits, potentially
typed and untyped alleles, and possible ambiguities),
which is mainly a scientific task of WG2. Here, the
role of WG3 is to provide computer facilities for the
application of the corresponding recommendations.
The programs being set up by WG3 are built on the
GENE[RATE] tools (http://geneva.unige.ch/generate/), the
formal specifications of which have been published by
Nunes et al. (2010, 2011b). At this level, two GENE
[RATE] programs are particularly useful:
1 phenotype to interpret raw phenotypes based on a
given reactivity data file and a kit description file;
and
2 transliterate to perform allele substitutions (e.g. to
recode 2nd field (protein level, formerly 4-digit)
alleles into 1st field (allele group level, formerly
2-digit) alleles) within a given dataset.
Another tool, uniformate, allows one to check the
validity of the data format before using any other
GENE[RATE] tool.
In this vein, some work has been devoted to the
adaptation of input formats to the guidelines recom-
mended by WG2, and this adaptation now allows run-
ning programs for standard one-locus analyses
(frequency estimation, Hardy–Weinberg equilibrium
and neutrality testing). On the other hand, the feasibil-
ity of a fully automatic recoding (through the GENE
[RATE] transliterate tool) of more complex (i.e. multilo-
cus) datasets is still progressing, as it faces the problem
of the identification of the potentially typed and un-
typed alleles at each locus and their combination
across distinct loci, as well as the standardization of
the procedure across multiple samples during the same
run.
An aspect of this issue relates to the use of heteroge-
neous and ⁄ or ambiguous data. Distinct samples col-
lected at different times or typed with distinct
techniques will not allow detecting the same alleles or
specificities. Thus, to compare samples of distinct
sources, the first step is to define the common set of
alleles over which to work. For each allele, we face
two extreme situations: the use of the unspecific first
field (formerly 2-digit) allele group and the use of the
precise allele defined at the highest resolution. Careful
scrutiny of the data generally provides an intermediate
solution where the most common allele pool between
several samples includes both ‘broad’ lineages for
some alleles and highly precise definitions for others.
Actually, within the framework of a HLA-NET-related
research project, we produced a set of programs
(‘SPLIT-TEST’) that provide help in screening the rawª 2012 Blackwell Publishing Ltd
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collection of samples. Recently, this ‘broad-split’ com-
puter tool has been applied successfully to study the
HLA molecular diversity of the Swiss bone marrow
donors’ registrees (Buhler, S., Nunes, J. M., Nicoloso,
G., Tiercy, J.-M. & Sanchez-Mazas, A. Submitted).
A challenge of this kind of work is to use information
as detailed as possible at the allelic level without com-
promising statistical power and without making too
many false-positive identifications. These two problems
have become significant with the advent of high-resolu-
tion typing because in this case, the vast majority of the
samples tested are too small in size to allow an accurate
identification of all existing alleles. This situation is even
worse when typing ambiguities are taken into account
(see discussion on the use of NMDP codes on paragraph
2.1). In this context, WG3 is thus also tackling the
important issue of ‘sample size and number of alleles’.
We are currently adapting a tool that will make easy to
estimate sample size thresholds and which will complete
the efforts of WG1 working on population sampling. It
is worth stressing that in general low allele or haplotype
frequencies are poorly estimated when sample sizes are
small and should be considered with caution. Even
detected alleles may actually be ‘nonsignificant’ from a
statistical point of view, depending on the sample size.
A very rough number for the minimal frequency of a
‘significant allele’ is given by the confidence interval of
the allele frequency obtained by normal (either two-tail
or one-tail) approximation (which is a standard statisti-
cal practice) or binomial distribution. For instance, for
a sample size of 50 individuals, all frequency estimates
smaller than 3.85% are ‘nonsignificant’ frequencies, i.e.
not significantly different from zero, because zero is
inside the two standard deviations’ confidence interval
(Table 4); in the same way, a 1% frequency is only ‘sig-
nificant’ for a sample larger than 200 individuals.
Therefore, because of the existent sampling conditions
where low sample sizes are usually the rule, HLA-NET
strongly recommends to avoid discussion on the ‘num-
ber of alleles present’ or ‘the presence or absence of
468 A. Sanchez-Mazas et al.given alleles’ in the populations where the samples were
drawn. Also, rather than to fix a minimal sample-size
threshold, a reasonable advice that can be given is to
use samples as large as possible.Population genetics with ambiguous data
Having mentioned the efforts to determine the actual
allele pool that can be used in a study, we now briefly
report the adaptation of the population genetic meth-
ods used for routine analyses. The former (15th) IHIW
workshop’s AHPD project held in Brazil in 2008 pro-
vided the framework to develop and test the GENE
[RATE] tools and their adequacy to the treatment of
ambiguous data, and these tools were further
expanded and generalized within the context of HLA-
NET. Besides their specific abstractions (data struc-
tures) used to capture ambiguous genetic data and the
definition of probability vectors to represent each indi-
vidual’s data, the main characterization of these pro-
grams is the use of resampling schemas to identify the
sampling distribution of each statistic (e.g. homozygos-
ity and linkage disequilibrium) of interest (Nunes
et al., 2011b). Currently, it is possible to estimate
allele frequencies, report frequencies graphically in the
form of bar charts with colour codes, test for Hardy–
Weinberg equilibrium and test for selective neutrality
on data containing any number and kind of ambigui-
ties (of course, if there are too many ambiguities the
results may be meaningless but that can generally be
controlled) by using the frequency estimation GENE
[RATE] tool (and haplotype to estimate haplotype fre-
quencies on multiple loci). Two other programs are
very useful in this context: file conversion allows one
to convert a file into different formats (e.g. from Excel
to the uniformate format used by GENE[RATE]), and, as
described above, uniformate allows one to check the
validity of the data format before using any other
GENE[RATE] tool. All details are given by Nunes et al.
(2010, 2011b) and the programs are available at
http://geneva.unige.ch/generate.Practical issues for population analyses
Although not yet definitive (ongoing work), the fol-
lowing HLA-NET WG3 recommendations correspond,
to our view, to the most important aspects of a popu-
lation analysis:
1 Genotypic data for given population samples (either
anthropologically defined or registry data) should be
complete and include all ambiguities; the format
used should be well known or explicitly described
(e.g. uniformat); NMDP codes should be avoided.
2 Data used for analyses should be retrieved from
genotypic data by recoding distinct sets of alleles
depending on the allelic pool of interest for a
given analysis (e.g. by using GENE[RATE] transliterate
tool).3 Sample sizes and the corresponding significant lev-
els of allele frequencies (based on standard devia-
tions) should be stated; the interpretation of the
frequencies should take into account these signifi-
cances and should avoid comparisons of
populations based on the presence or absence of
low-frequency alleles.
4 Reports of allele or haplotype frequencies should
mention the program and, possibly, the algorithm
used for estimation. Ideally, details about the ini-
tial conditions and environment of the algorithm
used should also be included (e.g. for an expecta-
tion-maximization (EM) algorithm: the number of
starting points, the number of distinct solutions,
and the convergence criteria, i.e. either on likeli-
hood or frequency values).
5 Assessment of Hardy–Weinberg equilibrium (HWE)
is mandatory for any use of allelic frequencies
describing the genetic profile of a population in
comparison to other data (otherwise phenotypic fre-
quencies should be used). Testing for HWE using
chi-square, G or exact tests on contingency tables
should only be done in the absence of ambiguities
and blank-like alleles. Otherwise, methods explicitly
accommodating ambiguities should be used, like the
method using nested likelihood ratios implemented
in the GENE[RATE] frequency estimation program.
6 Selective neutrality should be assessed at least by
reporting expected and observed homozygoties; a
formal test (e.g. the GENE[RATE] algorithm of
Ewens–Watterson test implemented in the frequency
estimation program) is however preferable.
7 One should use bar-chart graphics to represent fre-
quencies, rather than pie charts that are prone to
many errors for comparisons (see Tufte, 2001).
8 Proper studies should also include an account of
ethics as per WG4 recommendations.
An experiment is currently being made to accommo-
date this kind of meta-information described above in
the context of the AHPD project of the 16th IHIW
workshop. The WG3 group will evaluate the results
afterwards.
The issues mentioned above show that WG3 is ful-
filling its goals by providing a fully operational imple-
mentation of the guidelines emerging from HLA-NET.
Furthermore, given that the GENE[RATE] programs are
formally described, it will be easy to implement them
in other platforms developed for population genetic
analysis. The applicability of WG3 work thus extends
beyond its current GENE[RATE] implementation in the
HLA-NET platform.WG4 – Ethical issues
Aims of group
The role of working group 4 (WG4) is to provide sup-
port to the other working groups such that theirª 2012 Blackwell Publishing Ltd
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considerations. Much work has already been under-
taken to address ethical issues relating to genetic anal-
yses taking into account the interests of all the parties
involved in the study, i.e. researchers, participants and
society (Deschênes et al.; Robertson, 2003). It must be
stressed that population analysis of HLA types is not
equivalent to genetic screening for a mutation predic-
tive of disease and therefore the outcome of the HLA
analysis is less likely to have any impact on the partic-
ipants donating to the study.
It is not the aim of WG4 to reproduce (inter)na-
tional legislation and professional recommendations
that have been made elsewhere (Laberge, 2003) but to
look at the application of such recommendations to
HLA typing population studies specifically. In achiev-
ing our goals we aim to gather information related to
legal and ethical regulations in different countries and
to compile the information gained to obtain a consen-
sus on practice for European countries.Study plan
Overall, a thorough ‘study plan’ is key to the success of
any HLA population study, and this care must be
taken to ensure that the study conforms to national and
international legislation or recommendations ⁄ guide-
lines, where legislation is not in existence.
The study plan must be produced to provide infor-
mation required for approval by institutional review
board (IRB) or ethics committee. Even if the study is
already covered by existing ethics approval, it is rec-
ommended that complete documentation of the study
plan is produced.
The study plan must address the other following
aspects:Study aims
The aim of the population genetics study must be well
defined and documented prior to the study taking
place, i.e. which population will be studied and which
genetic loci will be analysed.Sampling
The following questions should be addressed:
1 Are there any risks and ⁄ or benefits to the subjects
participating in the study?
2 Is the collection of new samples required or will
DNA or other biological material already collected
be used?
3 Will the samples be anonymized? If yes, will this
happen at the point of collection or afterwards and
will the link between subject and sample be revers-
ible or irreversible. If reversible (also referred to as
‘identifiable’, ‘linked’ and ‘coded’), who is respon-
sible for the linking information?ª 2012 Blackwell Publishing Ltd
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stored?
Ethical issues relating to sampling individuals and
populations for genetic analysis have been reviewed
elsewhere and these apply to population studies of
HLA (Godard et al., 2003).
Samples already in collection
For samples that have already been collected, the con-
sent given at the time of collection must be reviewed
to see if the new proposed study qualifies. For exam-
ple, samples taken for clinical testing are unlikely to
have consent for unrelated HLA typing studies.
Depending on what consent has been given it may be
necessary to obtain additional consent and ⁄ or
IRB ⁄ ethics committee approval for the HLA popula-
tion genetics study. It is important to know whether
the samples can be identified or not. A recent case in
the USA highlighted that usage of previously collected
DNA from an Amerindian tribe was not undertaken
with appropriate consent from the participants (Cou-
zin-Frankel, 2010).Samples to be collected
Informed consent is required and ethical committee
approval must be sought. For informed consent to be
given, subjects must be deemed as competent to give
consent. Consent may be taken verbally or in writing
depending on local legislation and guidelines but in all
cases must be documented by the investigator.
The consent process must inform the subject, usually
through the issuing of an information sheet, of the fol-
lowing (McGuire & Beskow, 2010):
1 the nature and goals of the research study
2 the type of sample to be taken from the partici-
pant
3 what sort of tests will be performed on their sample
4 whether the samples are to be made available for
future undetermined studies
5 how data will be shared
6 what samples will be stored (intact cells, DNA)
7 length of storage, will this be limited
8 whether samples will be anonymized
9 freedom to withdraw from the study at any time
10 potential benefit or lack of benefit to participant
11 whether samples may be made available for other
ethically approved studies
If the collection of material is from a well-defined
population, it is appropriate to gain consent from
appropriate authoritative members of the community
and involve public consultation making use of local
media prior to embarking on collection.
Successful sample collection requires the concomitant
gathering of predetermined subject information (e.g.
470 A. Sanchez-Mazas et al.demographic and clinical data). The format of the data
to be collected for each subject donating a sample must
be predetermined and compatible with international
nomenclature and downstream data analysers.Examination process including data analysis
All biological material donated for research is extre-
mely valuable and maximum effort must be taken to
ensure that the material is tested by optimum proce-
dures that will ensure maximum benefit from the data
generated. Therefore the study plan must consider the
methods that will be utilized and whether these meth-
ods will be undertaken by qualified and experienced
personnel, e.g. HLA typing to be undertaken by an
EFI ⁄ ASHI-accredited laboratory that participates in
appropriate external proficiency testing for HLA typ-
ing. As the number of HLA alleles continues to increase
with time, all HLA typing population studies must
record the HLA allele database that has been used to
assign HLA types to subjects such that future analysis
can be undertaken should a new allele be found that
may have been masked by previous typings.
The analysis of the data must also be undertaken
using secure and proven software and should include
application of Hardy–Weinberg.
Decisions must be taken at the time of study design
to determine when resampling and ⁄ or retesting sam-
ples would be necessary.
For HLA typing data to accurately reflect the popu-
lation under study, care is required to minimize
unknown analysis of samples from individuals that are
related to one another; this may be more difficult to
determine for samples that are already in collection
and therefore the numbers of samples to be analysed
must be taken into consideration depending on
whether knowledge is available on relatedness within
population for optimum statistical evaluation.Data sharing
Consideration must be given to the following:
1 Data sharing with not-for-profit and for-profit orga-
nizations. Control of who has access to the data is
irrelevant if the data are made available via open
access data sharing. There is always the possibility
that the data obtained from the study could be used
to ultimately provide financial benefit, e.g. use of
HLA population data by commercial companies. A
risk assessment regarding this should be made for
each study and appropriate information given in the
study information guide given to participants.
2 It is also important to determine prior to embarking
on the sample collection whether the data should be
shared with the participants. If the samples are to
be anonymized then this is not possible and partici-
pants should understand this (Hull et al., 2008).The issue over whether it is ethical to deny genetic
research participant-individualized results have
been discussed by others (Affleck, 2009). If the shar-
ing of research results with participants is to be
undertaken this could be via a newsletter or a web-
site. This would allow a continued relationship with
the participants which may be important should
subsequent research studies be proposed with the
participants samples (Beskow & Smolek, 2009).
3 If samples are not fully anonymized, the identifi-
able material ⁄ data must be kept in a secure loca-
tion by the principle investigator only. Coded data
should only be shared.Sample handling and sample and data storage
It is crucial that sufficient finances are available to
cover secure storage of samples and data and that it is
clearly defined who has responsibility for samples,
their derivatives and the data generated.
There must also be secure procedures in place to
allow monitoring of the movement of data and sam-
ples (Godard et al., 2003).Conclusion and perspectives
In this study, each working group has made a number
of suggestions that can be taken as consensual HLA-
NET methodological recommendations. These preli-
minary recommendations will of course be refined dur-
ing the last period of the Action until their final
publication. Compared to other proposals aiming at
normalizing methodological issues in immunogenetic
studies involving HLA data (Hollenbach et al., 2011;
Nunes et al., 2011a), the present HLA-NET guidelines
are the results of a large collaborative effort aiming at
coordinating the whole suite of steps necessary to ana-
lyse HLA molecular data in human populations or reg-
istries, i.e. from population and ⁄ or sample definition
(WG1) to ethical considerations (WG4) via the report-
ing of typing results (WG2) and the statistical analysis
of the data (WG3). Also, it proposes very concrete
and immediately applicable solutions to common
problems (e.g. formatting data, estimating frequencies
with ambiguities) by opening the access to user-
friendly and continuously developing computer tools
(GENE[RATE]) to the whole community of researchers
working with this kind of data either at the population
or at the donor-registry level. Overall, following the
HLA-NET methodological recommendations given in
this study will help to synchronize the work done by
different laboratories to obtain comparable data and
facilitate both European and international collabora-
tion in histocompatibility, clinical transplantation, epi-
demiology and population genetics. At the end of the
HLA-NET Action, all final documents and guidelines
will be uploaded on a user-friendly HLA-NET public
platform, which will also offer direct access to data-ª 2012 Blackwell Publishing Ltd
International Journal of Immunogenetics, 2012, 39, 459–476
HLA-NET methodological recommendations 471bases linked to useful computer programs for HLA
data analysis. A joint effort with other consortiums
will further be undertaken to provide widely consen-
sual solutions at the international level.Acknowledgements
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HLA-NET methodological recommendations 473Appendix 1 Population data
questionnaireNote: This questionnaire is based on Geneva population questionnaire1. Institution providing the sample 
1.1 Name of the Institution:______________________________________________________
_______________________________________________________________________
1.2. Contact person (e.g. principal investigator):  
o Name: _______________________________________________________________
o Telephone number:_____________________________________________________
o E-mail address: ________________________________________________________
2. Sample tested 
(Please, fill one full questionnaire per sample) 
2.1 Type of study:
Field study in a well-defined population?            YES / NO 
If NO, please indicate which type of sample:  
o blood donors              YES / NO 
o stem cell donors (registries)            YES / NO 
o organ donors              YES / NO 
o cord blood donors              YES / NO 
o healthy controls for disease studies           YES / NO 
o patients               YES / NO 
o other, please specify             YES / NO 
_________________________________________________________
Does the sample include first degree relatives? YES / NO / UNKNOWN 
Is the information on relatedness available?            YES / NO 
2.2. Name of the population and any alternative names known (if necessary use Ethnologue):  
Main name (s): ___________________________________________________________
Other possible name(s): ____________________________________________________
________________________________________________________________________
Other specific characterization that would help to differentiate this population to any 
other (e.g., specific cultural trait like endogamy, specific religion, isolated location, etc):
________________________________________________________________________
________________________________________________________________________
2.3. Geographic location of the population:
Is the location of the sample the same as the location of the population?         YES / NO 
 If YES, fill the questionnaire only for the sample (1.3.1). 
 If NO (e.g. answer “NO” for Chinese living in US, etc), please fill the corresponding 
information for both the sample (1.3.1) and the population (1.3.2) from where the 
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Name of town(s) or village (s): ___________________________________________
Geographic coordinates (useful link to find coordinates):
o Latitude (in decimals, North or South): __________________________________
o Longitude (in decimals, East or West):___________________________________
o Altitude / environment (if relevant):_____________________________________




Name of town(s) or village (s): ___________________________________________
Geographic coordinates (useful link to find coordinates):
o Latitude (in decimals, North or South): __________________________________
o Longitude (in decimals, East or West):___________________________________
o Altitude / environment (if relevant):_____________________________________
Please attach a map if possible. Map included:           YES / NO 
2.3.3 Size of the population where the individuals were sampled (if known): __________
2.3.4 Other relevant information:____________________________________________
2.4 Language spoken by the population (please use Ethnologue)
Most specific language name (s): ____________________________________________
Linguistic family: ________________________________________________________
2.5 Other useful information about the general population (e.g. specific disease(s), 
demographic information, social structure, religion(s), etc (add pages if necessary):
Useful bibliographic references: _____________________________________________
3. Source of DNA & HLA typing 
3.1 Origin of DNA
Blood / mouth swabs / other (please underline the correct answer) 
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3.2 Loci typed and Methodology used for typing 
(Please follow the recommendation given at the end of the table)
Nb of individuals1 Locus typed2 Method3 Resolution Level4 Reference Date5
1 Number of individuals typed for each locus 
2 Locus options: A / B / C / DPA1 / DPB1 / DQA1 / DQB1 / DRB1 / DRB3 / DRB4 / DRB5 / MICA / KIR / OTHER 
3 Method options:  SSO / SSP / mono-allelic SBT / bi-allelic SBT. For SSO and SBT specify exon(s) typed. 
4 Resolution level options:  LOW / INTERMEDIATE / HIGH / ALLELIC 
5 Reference date:  IMGT/HLA-database version used to assign HLA Types  
4. Ethical considerations 
4.1 Informed consent 
Was informed consent obtained at time of sampling         YES / NO 
If yes, did this include 
o Transfer of data for analysis to third parties?         YES / NO 
o Storage of data in third party databases?         YES / NO 
If no or unknown:
o Is ethical review of the proposed data transfer necessary?       YES / NO 
4.2 Data
Was data anonymised?            YES / NO 
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476 A. Sanchez-Mazas et al.Appendix 2 guidelines for reporting HLA
typings
Typing Resolution
Whenever possible, perform allelic or high resolution
typing following EFI standard D1.320 and the docu-
ment ‘HARMONISATION OF DEFINITIONS OF
HISTOCOMPATIBILITY TYPING TERMS’ (see
http://hla.alleles.org).
a. Allelic resolution is a DNA-based typing result con-
sistent with a single allele as defined in a given ver-
sion of the WHO HLA Nomenclature Report.
b. High resolution is defined as a set of alleles that
specify and encode the same protein sequence for the
peptide binding region of an HLA molecule and that
excludes alleles that are not expressed as cell-surface
proteins. It identifies HLA alleles at the resolution
level of the 2nd field (formerly 4-digit) or more, at
least resolving all ambiguities resulting from polymor-
phisms located within exons 2 and 3 for class I loci,
and exon 2 for class II loci.
c. Intermediate resolution is defined as a DNA-based
typing result that includes a subset of alleles sharingthe digits in the first field of their allele name and that
excludes some alleles sharing this field.
d. Low resolution is a DNA-based typing result at the
level of the first field (formerly 2-digit) in the DNA-
based nomenclature. If none of the above resolutions
can be achieved, DNA-based low resolution typings
are accepted.Data with Ambiguities ⁄ high or Intermediate Resolution
In case allelic resolution is not achieved, data with
ambiguities are accepted in the following formats (in
preferential order):
I. List of possible genotypes (i.e. pairwise allelic combina-
tions) e.g. B*08:01:01G,B*15:18:01 or B*08:21,
B*15:93 or B*08:35,B*15:10:01 (corresponding to 3
possible combinations)
II. Allelic strings e.g. B*08:01 ⁄ 21 ⁄ 35,B*15:10 ⁄ 18 ⁄
93 (corresponding to 9 possible combinations)
III. NMDP codes e.g. B*08:MDY,B*15:DZBP (cor-
responding to 9 possible combinations)ª 2012 Blackwell Publishing Ltd
International Journal of Immunogenetics, 2012, 39, 459–476
